WashU Medicine Endocrinology

06/10/2026

Clinical research is essential to advancing patient care and developing innovative therapies, diagnostic tools, and medications. To learn more about our ongoing studies and current volunteer opportunities, please visit: http://bit.ly/427elza.

06/09/2026

Dr. Clair Crewe, lead author of a new study in Cell Press, uncovers how obesity disrupts the body's cellular messaging system. The findings suggest that impaired clearance of fat-cell extracellular vesicles may contribute to reduced insulin sensitivity and metabolic disease: bit.ly/4oiNI5G.

Clair Crewe, PhD Lead author Clair Crewe, PhD, Assistant Professor of Medicine in WashU Medicine’s Division of Cell Biology and Physiology and Division of Endocrinology, Metabolism and&nb…

06/08/2026

From diabetes to thyroid disorders, our specialized endocrine and metabolic care centers support patients every step of the way.
Expert care. Personalized treatment. Better outcomes.
Explore our locations and services: bit.ly/3MdYuGC.

06/05/2026

This week, we had the pleasure of celebrating our fellows at a farewell dinner, recognizing their dedication, hard work, and many contributions throughout their time with us. Thank you for everything, and congratulations on this next chapter. We wish you continued success!

06/03/2026

In case you missed it, check out our May e-newsletter to read about the latest that we've been up to: bit.ly/4o575iB.
Sign up to receive our monthly e-newsletters at: bit.ly/4l8jU9T.

06/02/2026

Congratulations to Dr. Jeffrey R. Millman on receiving funding from Breakthrough T1D to advance scalable stem cell-islet therapies for type 1 diabetes. His research aims to overcome key manufacturing barriers and to help bring high-quality, stem cell-derived islet therapies closer to patients living with type 1 diabetes: https://bit.ly/4dJob1T.

Jeffrey R. Millman, PhD, Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at WashU Medicine, has received research funding from Breakthrough T1D&nbs…

06/01/2026

Our Medicine Multispecialty Center has five locations where patients are seen for the diagnosis, treatment and management of endocrine and metabolic disorders. Learn more at https://bit.ly/3IuLzNM.

In the Medicine Multispecialty Center our physicians see patients for the diagnosis, treatment and management of endocrine and metabolic disorders such as thyroid diseases, adrenal and pituitary di…

05/28/2026

Hani Soudah, MD, PhD, Associate Professor of Medicine, Division of Endocrinology, Metabolism & Lipid Research, and collaborators have published a new systematic review and meta-analysis highlighting the broader physiological effects of semaglutide.

Their paper, titled **“A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition,”** goes beyond weight loss to explore how semaglutide may influence fat tissue, brain function, and cognitive health.

This work adds to our understanding of how GLP-1–based therapies may impact the body and brain, and could help guide future research on obesity, metabolism, and neurocognitive outcomes.

Read more about this important study and its implications for patient care and emerging treatment strategies > https://internalmedicine.wustl.edu/soudah-and-collaborators-review-semaglutides-metabolic-and-cognitive-effects/

05/27/2026

Dr. Anne Carol Goldberg co-authored a new study published in Nature Medicine exploring obicetrapib as a potential therapy for patients with heterozygous familial hypercholesterolemia and difficult-to-control LDL cholesterol: https://bit.ly/4uCnpK8.

Anne Carol Goldberg, MD, FACP Anne Carol Goldberg, MD, FACP, Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at WashU Medicine, is a co-author of a study pub…

05/26/2026

Phase 2 trial of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, a rare and progressive degenerative disease: https://doi.org/10.1172/JCI198519

Fumihiko Urano & team show treatment was associated with improved or stabilized pancreatic function, vision, and overall symptom burden.